|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, January 22, 2019 ) Top players in companion diagnostics market are F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (U.S.), and QIAGEN N.V. (Netherlands) dominated the global companion diagnostics market. Some of the other players competing in this market are Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Danaher Corporation (U.S.), Almac Group (U.S.), and Sysmex Corporation (Japan).
Get PDF Brochure of Companion Diagnostics Market Now available at http://www.rnrmarketresearch.com/contacts/request-sample?rname=209329 .
The global Companion Diagnostics Market is projected to reach USD 6.51 Billion by 2022 from USD 2.61 Billion in 2017, at a CAGR of 20.1%. The growth of this market is majorly driven by the factors such as improvements in regulatory guidelines, growing need for targeted therapies, rising cancer incidence across the globe, and increasing collaborations and partnerships for companion diagnostics test development.
Table of Content
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Companion Diagnostics Market, By Product & Service
7 Companion Diagnostics Market, By Technology
8 Companion Diagnostics Market, By Indication
9 Companion Diagnostics Market, By End User
10 Companion Diagnostics Market, By Region
11 Competitive Landscape
12 Company Profiles
12 Appendix
The key factors driving companion diagnostics market growth include increasing lung cancer cases, growing number of genetic testing, rising need for personalized medicines, and regulatory guidelines that support companion diagnostics market. Report analyzes companion diagnostics market by product & service, technology, indication, end user, & region.
Interested in this report, Get More information on Companion Diagnostics Market at https://www.whatech.com/market-research/medical/545480-companion-diagnostics-market-players-booming-investment-by-20-1-cagr-to-2023-scrutinized-in-new-research .
“The pharmaceutical & biopharmaceutical companies segment expected to grow at fastest CAGR”. On basis of end user, pharmaceutical & biopharmaceutical companies segment accounted for the largest share of market in 2016. This end-user segment also expected to register highest CAGR during forecast period. Large share & growth of this market can be attributed to increasing and significant application of companion diagnostics in drug development process.
Stakeholders of Companion Diagnostics Market
• Pharmaceutical and biotechnology companies
• Diagnostic manufacturers
• Research laboratories and academic institutes
• Research and development (R&D) companies
• Clinical research organizations (CROs)
Get Discount on “Companion Diagnostics Market by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022” report @ http://www.rnrmarketresearch.com/contacts/discount?rname=209329 .
The growth of Companion Diagnostics market is majorly driven by the factors such as improvements in regulatory guidelines, growing need for targeted therapies, rising cancer incidence across globe, and increasing collaborations and partnerships for companion diagnostics test development. Report analyzes the companion diagnostics market by product & service, technology, indication, end user, and region.
ReportsnReports
Snehal
+ 18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
